v3 Template
A

Aeovian Pharmaceuticals

Biopharmaceutical ~300 employees
Founded
--
Employees (Est.)
~300
15 leaders known
Total Funding
$55.0M
Funding Rounds
1
Last Funding
2025-12-16

About Aeovian Pharmaceuticals

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted and highly selective small molecules to restore cellular metabolic quality control, addressing dysregulated growth and hyperactive signaling in rare genetic and age-related diseases.

Products & Services

Small Molecule Therapies:Targeted and highly selective small molecules designed to restore cellular metabolic quality control for treating rare genetic and age-related diseases.

Specialties

Targeted small molecule development Cellular metabolic quality control Rare genetic diseases Age-related diseases

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series B
T: -
FT: Series B 		A: 55000000
MR: -
FA: $55 million
FAN: 55000000 		D: 2025-12-16
FD: 2025-12-16 		10 investors
Series B Latest
2025-12-16
$55.0M
10 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

A

Allison J. Hulme

Chief Executive Officer

J

John Kincaid

Chief Scientific Officer

D

Davis C. Ryman

Chief Medical Officer

M

Micah Zajic

Chief Financial Officer

R

Richard Gaster

Chairman & Director

L

Lars Ekman

Director

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

Aeovian Pharmaceuticals Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~300 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro